LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Strona główna・Stock List・United Therapeutics Corp

United Therapeutics Corp

Closed

SectorHealthcare

547.55 -0.34

Buy Sell

Overview

Share price change

24h

Current

Min

538.09

Max

550.83

Key metrics
By Trading Economics
Income	-89M 275M
Sales	-8.7M 782M
P/E Sector Avg	20.134 49.888
EPS	5.82
Profit margin	35.176
Employees	1,400
EBITDA	-176M 348M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+23.96% upside

Dividends
By Dow Jones
Next Earnings	29 lip 2026

Market Stats
By TradingEconomics
Market Cap	-1.5B 23B
Previous open	547.89
Previous close	547.55

News Sentiment

By Acuity

50%

154 / 344 Ranking in Healthcare

United Therapeutics Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 cze 2026, 23:22 UTC

Earnings

Major Market Movers

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 cze 2026, 23:09 UTC

Hot Stocks

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 cze 2026, 20:51 UTC

Earnings

Costco Reports 15% Sales Growth in May

3 cze 2026, 20:43 UTC

Earnings

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 cze 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 cze 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 cze 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 cze 2026, 23:15 UTC

Market Talk

Earnings

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 cze 2026, 22:08 UTC

Hot Stocks

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 cze 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 cze 2026, 21:18 UTC

Earnings

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 cze 2026, 21:15 UTC

Earnings

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 cze 2026, 21:13 UTC

Earnings

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 cze 2026, 21:13 UTC

Earnings

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 cze 2026, 21:12 UTC

Earnings

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 cze 2026, 21:09 UTC

Earnings

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 cze 2026, 21:03 UTC

Earnings

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 cze 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 cze 2026, 20:43 UTC

Earnings

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 cze 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 cze 2026, 20:37 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 cze 2026, 20:35 UTC

Earnings

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 cze 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 cze 2026, 20:17 UTC

Earnings

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 cze 2026, 20:17 UTC

Earnings

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 cze 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 cze 2026, 20:15 UTC

Earnings

Broadcom 2Q Adj EPS $2.44 >AVGO

3 cze 2026, 20:15 UTC

Earnings

Broadcom 2Q EPS $1.91 >AVGO

3 cze 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 cze 2026, 20:15 UTC

Earnings

Broadcom 2Q Rev $22.19B >AVGO

Peer Comparison

Price change

United Therapeutics Corp Forecast

Price Target

By TipRanks

23.96% upside

12 Months Forecast

Average 669.45 USD 23.96%

High 738 USD

Low 516 USD

Based on 11 Wall Street analysts offering 12 month price targets forUnited Therapeutics Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to United Therapeutics Corp - Dist in the past 3 months.

Sentiment

By Acuity

154 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.